Breaking News

inVentiv, Aprecia Enter Commercialization Pact

June 5, 2014

inVentiv to launch Aprecia brand and technology platform

inVentiv Health and Aprecia Pharmaceuticals entered an exclusive commercialization alliance for the launch the Aprecia brand and technology platform and initial pharmaceutical products.
Aprecia offers the ZipDose product platform using three-dimensional printing (3DP) technology to create fast-melt products. The company has completed clinical development and expects to file its first NDA with the FDA in 2H14. inVentiv will serve as Aprecia’s exclusive provider of commercialization services in exchange for future royalties on sales.
“Getting medicine into the human body reliably and accurately is both a challenge and an enormous opportunity,” said Don Wetherhold, chief executive officer of Aprecia. “To realize the potential of our technology and move quickly into market, we sought a partner that could execute every phase and function in commercialization, and inVentiv was the obvious choice.”
Michael Griffith, executive vice president of inVentiv Health, said, “We are pleased to have entered into this agreement with Aprecia and are looking forward to introducing their innovative technology platform and their much-needed products. Because of our unmatched expertise of pharmaceutical launches, clients know they can count on inVentiv Health to transform their assets into commercial success.”
  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO